Replies to post #170183 on Avid Bioservices Inc (CDMO)

[biopharm]

'Silo' one of healthcare's biggest flaws

April 10, 2014

To healthcare mogul Patrick Soon-Shiong, MD, the dirtiest four-letter word in the realm of digital health is "silo."

Unfortunately, it's everywhere. Hospitals, clinics and doctor's offices all keep close tabs on their information -- as do departments within the hospital or health network. Digital health devices and services silo their data, and let's not even talk about EHR vendors. In short, everyone in healthcare these days has control over a certain subset of data, and they're not into sharing.
..
..

.

http://www.healthcareitnews.com/news/silo-one-healthcares-biggest-flaws

So lets see now... Dr. Patrick Soon-Shiong is more the sharing type and that tells me he just may be all-in for a collaboration of a lifetime to start collecting some of that Big Data that he is thirsting for. Googles CALICO is all up Big Data as well.... one big happy family or is someone going to step forward to take control of all this Big Data sharing... time will tell

Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation, Chairman and CEO of the Institute for Advanced Health, Chairman and CEO of the Healthcare Transformation Institute and founder of the National Coalition for Health Integration.

http://www.healthcaretransformationinstitute.org/page/board-directors

--------------------------------

LONGEN ZHOU (ex-Peregrine)

Now: Head - Preclinical Biology at Chan Soon-Shiong Institute for Advanced Health

-------------------------------

Connecting some dots...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94588376

[biopharm]

March 14, 2014 - ties to David Parkinson...

David Mott ex-Ambit Director re: Ambit Biosciences Raises Over $49 Million in Series D Financing

Elliott Sigal(ex-BMS), M.D., Ph.D., New Enterprise Associates

Now.. Ambit BOD at 9 total -- including Mark Foletta - ex-BMS

ok... ever since the posts above... and links with Peregrine and Ambit has clearly been identified as collaborators, we continue to keep an eye on their BOD's -- because its all who you know and those coming into the BOD at Ambit just may be part of the game... BMS ?

---------------------

Ambit Biosciences Announces Changes To Board Of Directors

June 4, 2014

Ambit Biosciences AMBI -0.15% , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the appointment of Jeffrey S. Hatfield to its Board of Directors and the resignation of board member Steven Elms.

Mr. Hatfield currently serves as the CEO and board member of Vitae Pharmaceuticals, a clinical-stage company building a portfolio of compounds for diseases with significant unmet medical need. Prior to joining Vitae Pharmaceuticals, Mr. Hatfield worked as a senior executive at Bristol-Myers Squibb in a variety of positions....20 years at BMS ( Sr. VP Virology / Immunology ..Responsible for $1 billion US Virology and Immunology Divisions, including: clinical development, marketing, medical affairs, sales, policy, pricing and public and community relations and now deals with partnerships/collaborations..etc..)

http://www.marketwatch.com/story/ambit-biosciences-announces-changes-to-board-of-directors-2014-06-04

http://www.linkedin.com/pub/jeff-hatfield/6/ab2/20

-----------------------------------------------------


Jeffrey S. Hatfield

Chief Executive Officer, Vitae Pharmaceuticals, Inc.

Prior to joining Vitae Pharmaceuticals, Mr. Hatfield spent nearly 20 years at Bristol-Myers Squibb in a variety of operating positions of increasing responsibility, including, most recently, as Senior Vice President of its Virology and Immunology Divisions, where he was responsible for all aspects of a $1 billion business. Other senior level positions held at Bristol included President and General Manager, Canada, and Vice President, U.S. Managed Health Care. Mr. Hatfield holds a bachelor's degree in Pharmacy from Purdue University and an M.B.A. from The Wharton School, University of Pennsylvania.

http://www.vitaepharma.com/view.cfm/39/Jeffrey-S-Hatfield

-------------------------------------------------

Bipartisan bill would help biotechs fund research

June 9, 2014

The political environment in Washington is difficult, but this minor tax reform, which leverages provisions already within the tax code, is supported by a bipartisan group of senators and would have a tremendous impact on how our industry funds research.

A simple change in timing - reducing the wait to recognize tax assets from 15 years to zero - could make a world of difference. This small modification would enable biotech companies to apply research incentives when and how they are meant to be used: to enable us to fund groundbreaking scientific advancement that has the potential to change and save lives around the world.

The U.S. economy is bolstered by the high-quality jobs created by our industry, and supporting R&D is key to maintaining America's lead in the innovation-centric 21st-century economy. As an industry, we should be mindful of the importance of early-stage financing and the promise that early-stage research holds. By supporting the Start-up Jobs and Innovation Act, we can help Congress make the right decision for innovators, patients, and the country as a whole.

http://www.philly.com/philly/opinion/inquirer/20140609_Bipartisan_bill_would_help_biotechs_fund_research.html

[biopharm]

Now.. Ambit BOD at 9 total -- including Mark Foletta - ex-BMS

How many non-disclosure agreements have Peregrine made I wonder. Ambit was another one from the past... but all of a sudden gets bought out

It seems anything that touches PS Targeting attracts attention